Cyclophosphamide has been shown to deplete Tregs and boost the efficacy of vaccines in mouse models and CpG, which targets the toll-like receptor 9, reduces FoxP3+ cells in the lymph nodes of melanoma patients. The gene discussed is FOXP3; the disease is melanoma.